REG - Craneware plc - Holding(s) in Company

CranewareAnnouncement

18/06/2020 14:40

RNS Number : 4138Q
  
Craneware plc
  
18 June 2020
  
 

 
Craneware plc
("Craneware" or the "Company")
 
Holdings in the Company
 
18 June 2020 - The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle software solutions for the US healthcare market, has been notified that Derek Paterson, CIO of the Company, has today transferred 265,100 ordinary shares of 1p each in the Company ("Ordinary Shares") to members of his family, as part of his estate planning. The holdings shall be subject to certain lock-in arrangements.
 
Subsequent to this transaction, Mr. Paterson holds 622,872 Ordinary Shares in the Company, representing 2.3% of the issued share capital. 
 
 
 



NOTIFICATION OF MAJOR HOLDINGS 










1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: 


CRANEWARE PLC




1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)




Non-UK issuer








2. Reason for the notification (please mark the appropriate box or boxes with an "X")




An acquisition or disposal of voting rights


x




An acquisition or disposal of financial instruments








An event changing the breakdown of voting rights








Other (please specify)iii: 








3. Details of person subject to the notification obligationiv




Name


DEREK PATERSON




City and country of registered office (if applicable)


N/A




4. Full name of shareholder(s) (if different from 3.)v




Name


N/A




City and country of registered office (if applicable)


N/A




5. Date on which the threshold was crossed or reachedvi:


18/6/2020




6. Date on which issuer notified (DD/MM/YYYY):


18/6/2020




7. Total positions of person(s) subject to the notification obligation








% of voting rights attached to shares (total of 8. A)


% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)


Total of both in % (8.A + 8.B)


Total number of voting rights of issuervii




Resulting situation on the date on which threshold was crossed or reached


2.3%


N/A


2.3%


26,826,539




Position of previous notification (if 
applicable)


3.4%


N/A


3.4%


24,929,950












 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii




A: Voting rights attached to shares




Class/type of

shares
ISIN code (if possible)


Number of voting rightsix


% of voting rights




Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)




GB00B2425G68


622,872


N/A


2.3%


N/A
















































SUBTOTAL 8. A


622,872


2.3%




 
 




B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))




Type of financial instrument


Expiration

datex


Exercise/

Conversion Periodxi


Number of voting rights that may be acquired if the instrument is 
exercised/converted.


% of voting rights














































































SUBTOTAL 8. B 1












 
 




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))




Type of financial instrument


Expiration

datex


Exercise/

Conversion Period xi


Physical or cash 
settlementxii


Number of voting rights 


% of voting rights






























































































SUBTOTAL 8.B.2












 
 
 















 



9. Information in relation to the person subject to the notification obligation (please mark the 
applicable box with an "X")




Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii


X




Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)








Namexv


% of voting rights if it equals or is higher than the notifiable threshold


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold


Total of both if it equals or is higher than the notifiable threshold




























10. In case of proxy voting, please identify:




Name of the proxy holder


N/A




The number and % of voting rights held


N/A




The date until which the voting rights will be held


N/A










11. Additional informationxvi




Disposal is a transfer (including voting rights) to members of family under a "Deed of Gift"










 



Place of completion


Edinburgh, Scotland




Date of completion


18/6/2020



 
 
 
 
For further information, please contact:
 



Craneware plc


Peel Hunt (NOMAD & Joint Broker)                


Investec Bank (Joint Broker)


Alma (Financial PR)




+44 (0)131 550 3100


+44 (0)20 7418 8900


+44 (0)20 7597 5970


+44 (0)203 405 0205




Keith Neilson, CEO


Dan Webster 


Patrick Robb


Caroline Forde 




Craig Preston, CFO


George Sellar


Sebastian Lawrence


Helena Bogle








Andrew Clark


Henry Reast







 
About Craneware
 
Craneware (AIM: CRW.L), the leader in automated value cycle solutions, collaborates with U.S. healthcare providers to plan, execute and monitor value-based economic performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 350 staff. Craneware's value cycle management suite includes charge capture, strategic pricing, patient engagement, claims analytics, revenue recovery and retention, and cost and margin intelligence solutions. 
 
Learn more at www.craneware.com 
 
 
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
HOLFLFVVRRITLII